The Nephroprotective Effect of Mannitol in Head and Neck Cancer Patients Receiving Cisplatin Therapy
Show all authors
Erik Hägerström, Lotte Lindberg, Jens Bentzen, ...
First Published January 7, 2019 Research Article
Article information
Article has an altmetric score of 1 Open Access Creative Commons Attribution, Non Commercial 4.0 License
Abstract
Introduction:
Cisplatin is used as treatment for several different malignancies and a well-known complication is irreversible kidney damage. To protect the kidneys, this treatment is often combined with mannitol infusion to promote osmotic diuresis. Earlier studies investigating the nephroprotective effect of mannitol have shown conflicting results.
Objective:
To investigate changes in kidney function in head and neck cancer patients treated with cisplatin with and without additional mannitol infusion.
Methods:
A single center, retrospective cohort study of patients with squamous cell carcinoma of the head and neck receiving radiotherapy with cisplatin. Patient data were collected from November 2013 to December 2014.
Results:
After exclusion, a total of 78 patients were considered evaluable. They were equally distributed between a mannitol and a non-mannitol group and anthropomorphometrically similar. 51Cr-EDTA clearance declined in the mannitol group from 99.7 (19.9) to 96.4 (20.8) mL/min and in the non-mannitol group from 102.2 (17.8) to 92.3 (23.1) mL/min.
Conclusions:
There was a significantly smaller decrease in 51Cr-EDTA clearance in the mannitol group indicating a nephroprotective effect of mannitol.
Keywords Chemotherapy, head and neck cancer, toxicity management, hypopharyngeal cancer, laryngeal cancer, oropharyngeal cancer, radiotherapy, squamous cell carcinoma of the head and neck
References
1. De Conti, RC, Toftness, BR, Lange, RC, Creasey, WA. Clinical and pharmacological studies with cis-diamminedichloroplatinum (II). Cancer Res J. 1973;33:1310–1315.
Google Scholar
2. Leu, L, Baribeault, D. A comparison in the rates of cisplatin-induced nephrotoxicity associated with sodium loading or sodium loading with forced diuresis as a preventative measure. J Oncol Pharm Pract. 2010;16:167–171.
Google Scholar | SAGE Journals
3. Santoso, JT, Lucci, JA, Coleman, RL, Schafer, I, Hannigan, E. Saline, mannitol, and furosemide hydration in acute cisplatin nephrotoxicity: a randomized trial. Cancer Chemother Pharmacol. 2003;52:13–18.
Google Scholar | ISI
4. Morgan, KP, Buie, LW, Savage, SW. The role of mannitol as a nephroprotectant in patients receiving cisplatin therapy. Ann Pharmacother. 2012;46:276–281.
Google Scholar | SAGE Journals | ISI
5. Morgan, KP, Snavely, AC, Wind, LS. Rates of renal toxicity in cancer patients receiving cisplatin with and without mannitol. Ann Pharmacother. 2014;48:864.
Google Scholar
6. McKibbin, T, Cheng, LL, Kim, S. Mannitol to prevent cisplatin-induced nephrotoxicity in patients with squamous cell cancer of the head and neck (SCCHN) receiving concurrent therapy. Support Care Cancer. 2016;24:1789–1793.
Google Scholar | ISI
7. Bentzen, J, Toustrup, K, Eriksen, JG, Primdahl, H, Andersen, LJ, Overgaard, J. Locally advanced head and neck cancer treated with accelerated radiotherapy, the hypoxic modifier nimorazole and weekly cisplatin. Results from the DAHANCA 18 phase II study. Acta Oncol. 2015;54:1001–1007.
Google Scholar
8. Hosmer, DW, Lemeshow, S, Sturdivant, RX. Applied Logistic Regression. 3rd ed. London, England: Wiley; 2013.
Google Scholar
9. Fox, J, Weisberg, S. An {R} Companion to Applied Regression. 2nd ed. Thousand Oaks, CA: SAGE; 2011.
Google Scholar
10. Yoshida, K, Bohn, J. tableone: create "Table1" to describe baseline characteristics (R package version 0.7.3).http://CRAN.R-project.org/package=tableone. Published 2015.
Google Scholar
11. Fitzmaurice, GM, Laird, NM, Ware, JH. Applied Longitudinal Analysis. 2nd ed. London, England: Wiley; 2011.
Google Scholar
12. Lindberg, L, Brødbæk, K, Hägerström, EG, Bentzen, J, Kristensen, B, Zerahn, B. Comparison of methods for estimating glomerular filtration rate in head and neck cancer patients treated with cisplatin. Scand J Clin Lab Invest. 2017;77:237–246.
Google Scholar
Similar Articles:
No comments:
Post a Comment